ALVO Company Profile and Key Details
NASDAQ : ALVO
Alvotech
$3.28
0.03+0.92%
At Close 4:00 PM50
B-ESG ScoreESG Rating
Price Chart
Stock Price Today
Alvotech (ALVO) stock surged +0.92%, trading at $3.28 on NASDAQ, up from the previous close of $3.25. The stock opened at $3.25, fluctuating between $3.20 and $3.32 in the recent session.
Stock Snapshot
3.25
Prev. Close
1.02B
Market Cap
3.2
Day Low
32.8
P/E Ratio
0.1
EPS (TTM)
-1.34
Cash Flow per Share
3.25
Open
312.05M
Number of Shares
3.315
Day High
37.57%
Free Float in %
-3.49
Book Value
275.76K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 19, 2026 | 3.24 | 3.32 | 3.20 | 3.28 | 277.27K |
| May 18, 2026 | 3.30 | 3.36 | 3.22 | 3.25 | 361.81K |
| May 15, 2026 | 3.41 | 3.42 | 3.27 | 3.31 | 683.7K |
| May 14, 2026 | 3.67 | 3.69 | 3.42 | 3.43 | 342.35K |
| May 13, 2026 | 3.51 | 3.73 | 3.44 | 3.67 | 527.7K |
| May 12, 2026 | 3.59 | 3.59 | 3.38 | 3.55 | 377.37K |
| May 11, 2026 | 3.41 | 3.74 | 3.36 | 3.59 | 606.78K |
| May 08, 2026 | 3.21 | 3.32 | 3.17 | 3.26 | 469.19K |
| May 07, 2026 | 3.31 | 3.44 | 3.18 | 3.20 | 715.92K |
| May 06, 2026 | 3.53 | 3.61 | 3.39 | 3.57 | 440.29K |
| May 05, 2026 | 3.57 | 3.61 | 3.47 | 3.50 | 208.21K |
| May 04, 2026 | 3.47 | 3.57 | 3.46 | 3.52 | 152.16K |
| Apr 30, 2026 | 3.31 | 3.37 | 3.31 | 3.34 | 246.98K |
| Apr 29, 2026 | 3.50 | 3.53 | 3.30 | 3.30 | 407.27K |
| Apr 28, 2026 | 3.35 | 3.55 | 3.33 | 3.52 | 509.27K |
| Apr 27, 2026 | 3.40 | 3.48 | 3.30 | 3.30 | 411.12K |
| Apr 23, 2026 | 3.50 | 3.50 | 3.35 | 3.38 | 462.93K |
| Apr 22, 2026 | 3.53 | 3.63 | 3.46 | 3.50 | 336.91K |
| Apr 21, 2026 | 3.63 | 3.72 | 3.51 | 3.51 | 650.68K |
| Apr 20, 2026 | 3.61 | 3.66 | 3.46 | 3.62 | 196.89K |
Contact Details
About Company
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Company Information
| Employees | 1012 |
| Beta | 0.25 |
| Sales or Revenue | $91.43M |
| 5Y Sales Change% | 2.071% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Stock Peers
NBIX
-2.85-1.81%
Neurocrine Biosciences, Inc.$154.36ITCI00
Intra-Cellular Therapies, Inc.$131.87LNTH-0.24-0.26%
Lantheus Holdings, Inc.$92.89ANIP0.98+1.24%
ANI Pharmaceuticals, Inc.$80.32SUPN-0.71-1.47%
Supernus Pharmaceuticals, Inc.$47.62INDV0.45+1.23%
Indivior Pharmaceuticals Inc$36.99PAHC-0.28-0.82%
Phibro Animal Health Corporation$33.90COLL-0.03-0.09%
Collegium Pharmaceutical, Inc.$33.62PETQ-0.01-0.03%
PetIQ, Inc.$30.98HROW-0.22-0.71%
Harrow Health, Inc.$30.68Company Overview
Alvotech (NASDAQ:ALVO) closed at $3.28 USD, gaining $0.03 (0.92%) from the previous close of $3.25. The stock is currently mid-range between its 52-week high and low $3.03 and $11.85. With a market capitalization of about $1.02 billion, Alvotech is classified as a small-cap and shows lower-than-market volatility (beta ~0.21). Key stats such as the average daily volume over the past year has been around 523.77 thousand shares, volume is running light vs its 52-week average. Headquartered in Luxembourg, None, Alvotech operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Lisa Graver, the company employs approximately 1,012 people and listed since June 16, 2022. Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
Technical Performance
ALVO has shown mixed momentum, gaining 0.61% over the past week and -43.12% over the past quarter, though year-to-date performance is down -3.31%. Short-term trend indicators are bullishly aligned (SMA20 -12.52%, SMA50 -15.15%, SMA200 -43.76%). The stock’s 14-day RSI is 30.62 (weak momentum), while the ATR of 0.26 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -65.01% below its high and over 5.85% above its low. Average 10-day trading volume of 453.85 thousand shares is below the 3-month average of 520.57 thousand, indicating normal recent market interest.
Valuation Metrics
Alvotech trades at a P/E ratio of 32.7, slightly above the S&P 500 average, with a price-to-sales ratio of 1.74 and a price-to-book ratio of -3.21 indicating negative book value, which may reflect financial stress. The P/FCF stands at -8.9, also above market averages.
Dividend & Fair Value
Dividend and splits history remains an important factor for investors monitoring long-term returns.
Earnings & Analyst Outlook
Alvotech generated EPS of $0.23 over the past year. Five-year average earnings growth is -30.68%. The latest quarter delivered EPS of -$0.09. The next quarter is forecast at $0.00. Next year's EPS is expected at $67.57. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 8 Buy ratings, 1 Hold ratings, 0 Sell rating and 2 Strong Sell ratings. Price targets range from $14.00 to $4.00. The high target offers 326.83% upside. The low target suggests 21.95% downside. The mean target is $10.92. This offers 232.93% upside. Alvotech earnings surprise history is a mixed track record. The quarter that ended May 06, 2026, missed forecasts by 28.57%. The prior quarter beat by 6334.78%. Over the last six quarters, Apple has recorded several small beats. These include -38.46% in March 26, 2025.
Shareholding & Insider Activity
Alvotech has 312.05 million shares outstanding. The public float is 114.09 million shares, elevated short interest at 2.05% of float. This equals 2.37 million shares. The short ratio is 5.76 days. Institutional investors hold 15.3% of the float. Insiders own 61.77%.
Financial & Profitability Overview
On valuation metrics, Alvotech trades at a P/E of 32.70, P/S of 1.74 and P/B of -3.21. The current ratio is 1.89 and quick ratio is 1.16. Operationally, the company’s inventory turnover is 1.07 and cash conversion cycle is 188.96 days. Debt-to-equity is -5.09, supported by a cash flow-to-debt ratio of -0.03.
Quarterly Financial Highlights
The company ended the quarter with $11.16M in cash and short-term investments, a total debt of $1.08B, and net debt of $1.06B. Total assets were $950.09M, with equity of - $932.49M. Financials further reflected weakness, with operating cash flow of - $312.19M, free cash flow of - $358.66M, and capital expenditures of - $46.47M.
Price Forecast & Outlook
Our AI price prediction model suggests that Alvotech stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.13%, with price expected at $3.21 by June 02, 2026, within a range of $3.02 to $3.38 3-Month Outlook: Projected fall of -4.27%, reaching $3.14 by August 14, 2026, with a range of $2.95 to $3.35. 1-Year Outlook: Projected loss of -68.6%, with price at $1.03 by May 19, 2027, within a range of $0.00 to $0.00.
Key Takeaways
Alvotech (NASDAQ:ALVO) shares are flat -3.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Alvotech trading at a premium to the broader market with a P/E of 32.7. Analyst sentiment is cautious, with the majority of ratings in Underweight territory and a mean price target of $11.52, suggesting 251.22% upside. Our AI forecast model points to short-term weakness (-2.13% over two weeks), a medium-term fall (-4.27% over three months), and a longer-term loss (-68.6% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Alvotech (ALVO) stock price?
Alvotech (NASDAQ: ALVO) stock price is $3.28 in the last trading session. During the trading session, ALVO stock reached the peak price of $3.32 while $3.20 was the lowest point it dropped to. The percentage change in ALVO stock occurred in the recent session was 0.92% while the dollar amount for the price change in ALVO stock was $0.03.
ALVO's industry and sector of operation?
The NASDAQ listed ALVO is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Alvotech designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of ALVO?
Mr. Robert Wessman
Founder & Executive Chairman of Directors
Mr. Mark Levick
Chief Executive Officer
Ms. Sigridur Elin Gudlaugsdottir
Vice President of HR
Mr. Joel Morales
Chief Financial Officer
Dr. Hafrun Fridriksdottir Ph.D.
Chief Operating Officer
Mr. Giedrius Zunda
Chief Technical Officer
Mr. Joseph E. McClellan
Chief Scientific Officer
Ms. Tanya Zharov
Gen. Counsel
Mr. Sean Gaskell
Chief Technical Officer
Ms. Rose-Marie Ohlsson
Chief Information Officer
Mr. Anil Okay
Chief Commercial Officer
Ms. Eva Yr Gunnlaugsdottir
Vice President of People & Culture
Founder & Executive Chairman of Directors
Mr. Mark Levick
Chief Executive Officer
Ms. Sigridur Elin Gudlaugsdottir
Vice President of HR
Mr. Joel Morales
Chief Financial Officer
Dr. Hafrun Fridriksdottir Ph.D.
Chief Operating Officer
Mr. Giedrius Zunda
Chief Technical Officer
Mr. Joseph E. McClellan
Chief Scientific Officer
Ms. Tanya Zharov
Gen. Counsel
Mr. Sean Gaskell
Chief Technical Officer
Ms. Rose-Marie Ohlsson
Chief Information Officer
Mr. Anil Okay
Chief Commercial Officer
Ms. Eva Yr Gunnlaugsdottir
Vice President of People & Culture
How ALVO did perform over past 52-week?
ALVO's closing price is 8.25% higher than its 52-week low of $3.03 where as its distance from 52-week high of $11.85 is -72.32%.
How many employees does ALVO have?
Number of ALVO employees currently stands at 1,012.
Link for ALVO official website?
Official Website of ALVO is: https://www.alvotech.com
How do I contact ALVO?
ALVO could be contacted at phone 354 422 4500 and can also be accessed through its website. ALVO operates from Saemundargata 15-19, Luxembourg, 102, Iceland.
How many shares of ALVO are traded daily?
ALVO stock volume for the day was 275.76K shares. The average number of ALVO shares traded daily for last 3 months was 523.78K.
What is the market cap of ALVO currently?
The market value of ALVO currently stands at $1.02B with its latest stock price at $3.28 and 312.05M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep